Biguanides Market Report 2026

The biguanides market size has grown steadily in recent years. It will grow from $5.11 billion in 2025 to $5.28 billion in 2026 at a compound annual growth rate (CAGR) of 3.4%. The growth in the historic period can be attributed to increasing prevalence of type 2 diabetes, rising awareness of metabolic disorders, growth in generic biguanides availability, adoption of oral antidiabetic medications, advancements in liver-targeted therapies.

The biguanides market size is expected to see steady growth in the next few years. It will grow to $5.97 billion in 2030 at a compound annual growth rate (CAGR) of 3.1%. The growth in the forecast period can be attributed to growing demand for personalized medicine, expansion of telemedicine for diabetes care, rising incidence of pcOS, development of combination therapies, government initiatives promoting chronic disease management. Major trends in the forecast period include personalized diabetes management solutions, combination therapy development, expanded indications beyond type 2 diabetes, home healthcare & remote patient monitoring, cost-effective generic biguanides.

The increasing prevalence of diabetes is anticipated to drive expansion in the biguanides market. Diabetes represents a chronic metabolic condition marked by high blood glucose levels resulting from inadequate insulin production or ineffective insulin action. This surge in diabetes stems from shifts in lifestyle, an aging population, and greater awareness through diagnostics. Biguanides aid in managing diabetes by enhancing insulin sensitivity, curbing glucose output from the liver, and assisting in blood sugar reduction for those with type 2 diabetes. For instance, in March 2024, data from the Office for Health Improvement & Disparities (OHID), a UK government body, showed that from March 2022 to March 2023, the share of type 1 diabetes patients completing all eight recommended care processes rose by 22%, with a 21% increase for type 2 diabetes, and the percentage meeting target HbA1c levels hit 37.9% - the highest on record. Thus, the growing incidence of diabetes is fueling biguanides market growth.

Major companies in the biguanide market are prioritizing the development of innovative solutions like extended-release biguanide formulations to boost patient compliance, optimize glycemic control, and reduce gastrointestinal side effects. Extended-release biguanide formulations are medications engineered to release their active ingredient slowly over time, ensuring steady blood levels, better tolerability, and stronger long-term adherence for people managing diabetes. For example, in August 2023, Dr. Reddy’s Laboratories, an India-based biotech firm, introduced saxagliptin and metformin hydrochloride extended-release tablets - a USFDA-approved generic equivalent of KOMBIGLYZE XR that pairs saxagliptin, a DPP-4 inhibitor, with metformin, a biguanide - providing adults with type 2 diabetes a convenient once-daily option that aids glycemic control alongside diet and exercise, while its extended-release mechanism promotes greater adherence.

In August 2023, Lupin, an India-based biopharmaceutical firm, purchased the diabetes brands ONDERO and ONDERO MET from Boehringer Ingelheim for an undisclosed sum. This deal bolsters Lupin’s standing in the anti-diabetes market by broadening its lineup with proven oral antidiabetic treatments. It also boosts the company’s capacity to enhance patient access to vital diabetes drugs and solidifies its rivalry in the metabolic disorders sector. Boehringer Ingelheim, a Germany-based biopharmaceutical firm, focuses on researching, developing, and manufacturing therapies for human and veterinary use.

Major companies operating in the biguanides market are Pfizer Inc., Sanofi-Aventis LLC, Viatris Inc., Aurobindo Pharma Ltd., Cipla Ltd, Dr. Reddy's Laboratories, Lupin Limited, Zydus Lifesciences Limited, Torrent Pharmaceuticals Limited, Intas Pharmaceuticals Ltd., Apotex Inc, Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Ltd., Mylan Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Panacea Biotech Ltd., Wanbury Ltd, USV Private Limited, Abbott Laboratories.

Asia-Pacific was the largest region in the biguanides market in 2025. Middle East And Africa is expected to be the fastest-growing region in the forecast period. The regions covered in the biguanides market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the biguanides market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the biguanides market by increasing the cost of imported raw materials and active pharmaceutical ingredients (APIs), leading to higher production costs and potential delays in supply chains. Regions like Asia-Pacific, which are major manufacturing hubs for biguanides, are most impacted, particularly for metformin and extended-release formulations. Hospital and retail pharmacy segments may face temporary price increases, while local manufacturers might benefit from protective measures, encouraging domestic production and reducing dependency on imports. Overall, the tariffs have a mixed impact, creating challenges in cost management but potential incentives for local manufacturing.

The biguanides market research report is one of a series of new reports that provides biguanides market statistics, including biguanides industry global market size, regional shares, competitors with a biguanides market share, detailed biguanides market segments, market trends and opportunities, and any further data you may need to thrive in the biguanides industry. This biguanides market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Biguanides are a class of drugs mainly prescribed for type 2 diabetes treatment. They reduce blood sugar by decreasing hepatic glucose production and enhancing insulin sensitivity. These drugs also manage polycystic ovary syndrome (PCOS) and various metabolic conditions.

The primary biguanides include metformin, phenformin, and several others. Metformin stands out as a commonly prescribed biguanide drug for managing type 2 diabetes by reducing blood glucose levels. It comes in multiple dosage forms, such as tablets and oral solutions, available in options like immediate-release and extended-release, and is distributed through channels including hospital pharmacies, retail pharmacies, and online pharmacies.

The biguanides market consists of sales of Chlorhexidine, Polyhexanide, Proguanil, and Buformin. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.